1. Analysis of L-DOPA and droxidopa binding to human β2-adrenergic receptor
- Author
-
Vincenzo Barone, Giordano Mancini, Akash Deep Biswas, Andrea Catte, Biswas, A. D., Catte, A., Mancini, G., and Barone, V.
- Subjects
Agonist ,Adrenergic receptor ,medicine.drug_class ,Biophysics ,chemistry.chemical_compound ,chemistry ,Dopamine ,Docking (molecular) ,medicine ,Droxidopa ,Binding site ,Receptor ,Settore CHIM/02 - Chimica Fisica ,medicine.drug ,G protein-coupled receptor - Abstract
Over the last two decades, an increasing number of studies has been devoted to a deeper understanding of the molecular process involved in the binding of various agonists and antagonists to active and inactive conformations of β2-adrenergic receptor (β2 AR). The 3.2 A X-ray crystal structure of human β2 AR active-state in combination with the endogenous low affinity agonist adrenaline offers an ideal starting structure for studying the binding of various catecholamines to adrenergic receptors. We show that molecular docking of L-DOPA and Droxidopa into rigid and flexible β2 AR models leads for both ligands to binding anchor sites comparable to those experimentally reported for adrenaline, namely D113/N312 and S203/S204/S207 side chains. Both ligands have a hydrogen bond network that is extremely similar to those of noradrenaline and dopamine. Interestingly, re-docking neutral and protonated versions of adrenaline to rigid and flexible β2 AR models results in binding poses that are more energetically stable and distinct from the X-ray crystal structure. Similarly, lowest energy conformations of noradrenaline and dopamine generated by docking into flexible β2 AR models had binding free energies lower than those of best poses in rigid receptor models. Furthermore, our findings show that L-DOPA and Droxidopa molecules have binding affinities comparable to those predicted for adrenaline, noradrenaline, and dopamine, which are consistent with previous experimental and computational findings and supported by the MD simulations of β2AR-ligand complexes performed here. SIGNIFICANCE The β2-adrenergic receptor (β2 AR), which belongs to the vast family of Guanine nucleotide-binding protein coupled receptors (GPCRs), is a transmembrane protein that is activated by the catecholamines norepinephrine (noradrenaline) and epinephrine (adrenaline). Using molecular docking methods, we discovered that the exogenous ligands L-DOPA and Droxidopa have the same hydrogen bond binding sites as endogenous agonists such as adrenaline, noradrenaline, and dopamine. Furthermore, all of the catecholamines studied had different hydrophobic binding sites in the receptor. Our findings might help researchers to better understand how existing and new drugs chemically similar to Droxidopa, which is used to treat Parkinson's disease, interact with β2 AR.
- Published
- 2021
- Full Text
- View/download PDF